NVO Share Price: From GLP-1 Gold Rush to Market Reality

Even when investors wish they would, the screens on the trading floor are honest. The price of NVO shares as of this week is about $38, which is close to its 52-week low of $38.36. That figure has psychological significance. Novo Nordisk was riding the GLP-1 obesity wave like a biotech darling with unstoppable momentum, flirting with $90 not long ago. Even cautious, the stock feels bruised now.

It’s difficult to ignore how quickly the reversal is happening. The price of NVO shares has dropped over 50% in the last year, slipping through what once appeared to be strong support levels. Following CagriSema’s disappointing trial results, shares fell precipitously over the course of five days, at one point plunging more than 15% intraday. There was a certain weight to the sell-off, as if long-term holders were reconsidering their beliefs.

At least in the public eye, the catalyst was clinical. Eli Lilly and Company’s Zepbound, a weight-loss medication that contains tirzepatide, was more effective than Novo’s next-generation obesity candidate. In a market that is fixated on percentages, minor variations can turn into multibillion-dollar stories (23% weight loss versus 25.5%). Investors appear to think that the obesity drug industry is a winner-take-all situation. Second place seems pricey.

However, there were other tremors besides the disappointment of the trial. An additional degree of uncertainty was introduced by Novo’s decision to reduce Ozempic and Wegovy’s U.S. list prices by as much as 50%. When I heard a customer inquire about insurance coverage for Wegovy last week while I was standing in a pharmacy in Manhattan, it became evident how much perception is influenced by price. While lowering prices can increase accessibility, it also reduces profit margins. Whether volume growth can completely counteract that trade-off is still up in the air.

On paper, the fundamentals don’t appear to be very bad. Novo’s price-to-earnings ratio is approximately 11, which is significantly lower than the stretched multiples observed during the GLP-1 mania. Last fiscal year, net income surpassed $15 billion, and revenue surpassed $46 billion. There is some comfort in the dividend yield, which is between 3% and 4%. When contrasted with soaring tech stocks, this appears to be nearly conservative.

However, sentiment is not influenced by numbers alone. It’s momentum. Additionally, the NVO share price chart depicts a 20-month downward trend that has only recently shown hints of stabilization. In an attempt to form a base, technical traders look to the 200-day moving average while observing RSI divergence. An investment thesis may be a hope. However, it’s rarely enough.

Lilly is not the only competitor. Smaller biotech companies and Pfizer are joining the obesity race by creating combination therapies and oral GLP-1 candidates. Novo recently entered into a $2.1 billion deal with Vivtex to expand into the oral biologics market. There is a sense of urgency as management changes course and announces alliances while protecting its franchise. The leadership is aware that the window is closing.

Fundamentally, Novo continues to dominate the global market for branded diabetes treatments, holding about a third of the market. It’s long-acting insulin, Tresiba, used to represent power. However, since 2017, competition from biosimilars and pressure on U.S. prices have eroded that confidence. These pressures were momentarily obscured by the obesity epidemic. They are once more in view, subtly raising expectations.

The mood of the market doesn’t help. The S&P 500 and Nasdaq, two of the larger indices, have been erratic in response to headlines about tariffs, changes in interest rates, and disruptions from AI. Healthcare stocks occasionally take a defensive stance in that setting. At other times, they end up as collateral harm. The price of NVO shares appears to be in the middle, neither obviously defensive nor growth-oriented.

The opinions of analysts are divided: about half lean “buy,” a sizable portion advise “hold,” and a vocal but small minority advise “sell.” The psychology of investors is reflected in that split. A discounted global leader with steady cash flow and a pipeline that can still pull off surprises is what some see. Others believe that a business is losing its narrative advantage just as competition is getting fiercer.

Earlier this week, as I passed a financial news studio, the ticker read, “Novo Nordisk Shares Plunge After Trial Setback.” There was something theatrical about the language. Markets, however, are rarely that simple. A century-old business that was established in 1923 is not destroyed by a single trial. A price reduction also doesn’t indicate surrender. It might actually be a strategic realignment, giving up short-term profits to protect long-term market share.

Whether Novo survives is not the question that looms over the price of NVO shares. It most likely will. Valuation is the more profound question. Was the prior peak around $93 a speculative overshoot driven by euphoria from GLP-1? Is the $38 level today too negative, pricing in too much bad news too soon?

Even though their gains are smaller, investors who bought the stock when it was in the teens ten years ago are still in possession of it. By entering at these levels, new purchasers are essentially placing bets that, despite price wars and clinical competition, obesity and diabetes treatments will continue to be growth engines.

It seems like the upcoming quarters will be more significant than usual. Real-world demand data, pipeline updates, and earnings reports will either strengthen doubts or confirm resilience. The NVO share price is no longer just a momentum story, as can be seen as this plays out with screens flickering red and green. It’s a test of belief and patience.